Use of a catalytic co-solvent, N,N-dimethyl octanamide, allows the flow synthesis of Gleevec with no solvent switch by Yang, Jeffrey et al.
COMMUNICATION          
 
 
 
 
 Use of a "Catalytic" Cosolvent, N,N-Dimethyl Octanamide, Allows the Flow 
Synthesis of Imatinib With No Solvent Switch 
 Jeffrey C. Yang, Dawen Niu, Bram Karsten, Fabio Lima and Stephen L. Buchwald*[a] 
Abstract: A general, efficient method for C−N cross-coupling has 
been developed using N,N-dimethyloctanamide as a “catalytic” 
cosolvent for biphasic continuous-flow applications. The described 
method was used to generate a variety of biarylamines and was 
integrated into a two-step sequence that converted phenols into 
biarylamines via the intermediacy of triflates or toslates. Additionally, 
the method was applied to a three-step synthesis of imatinib, the API 
of Gleevec® in good yield without the need of solvent switches. 
The use of continuous-flow technology in synthesis has 
received an increasing amount of attention over the past decade 
in both academia and industry.1 Compared to traditional batch 
methods, continuous-flow offers many benefits, including safer 
manipulation of reactions at high pressure and temperature, the 
ability to scale chemical reactions in a more straightforward 
manner, and the in-situ generation and consumption of 
intermediates, thus combining multiple synthetic steps into a 
single process.1,2 
The importance of aromatic amines and their derivatives is 
demonstrated by their prevalence in pharmaceutical agents and 
organic materials. Palladium catalyzed C–N cross-coupling3 has 
become a widely applied method for the preparation of these 
compounds. As a continuation of our interest in developing 
practical methods for C–N bond construction, we initiated a 
program for the development of general methods to perform 
palladium-catalyzed amination in continuous-flow reactors.4   
Previous studies by us and other research groups have revealed 
several difficulties with transitioning C–N cross-coupling to 
continuous-flow conditions.5 The formation and precipitation of 
crystalline products and inorganic salts during cross-coupling 
reactions often results in clogging of the continuous-flow 
reactorMoreover, downstream solvent switches are often 
required due to the limited range of solvents suitable for cross-
coupling. The formation of byproducts may also impact 
downstream reactions, thus complicating multistep synthesis in 
a continuous flow reactor. As a consequence, multistep 
continuous flow processes that utilize a C–N cross-coupling step 
remain rare.  
A large body of work has demonstrated the advantages of 
amphiphilic organic solvents and additives in batch chemistry.16 
Amphiphilic solvents facilitate contact between organic- and 
water-soluble components of a reaction while maintaining a high 
local concentration of the organic reactants, thereby accelerating 
mass transfer and overall reaction rates. In addition to these 
benefits, amphiphilic solvents are capable of solubilizing a wide 
range of compounds, which may mitigate crystallization and 
minimize the need for solvent switches in a multistage 
continuous flow process. As a result, we believed that the use of 
organic amphiphiles in biphasic solvent systems might permit a 
broader range of C–N cross-coupling reactions to be performed 
under continuous flow conditions. 
 
 
Figure 1. Properties of N,N-dimethyloctanamide 
 
Here we report the identification and use of N,N-
dimethyloctanamide (DMO, 1, Figure 1) as an amphiphilic 
organic co-solvent that enabled the synthesis of a wide range of 
(hetero)arylamines via palladium catalyzed C–N cross-coupling 
reaction under continuous flow conditions. Furthermore, we 
demonstrate that this method could be integrated into a two-step 
sequence for the direct conversion of phenols to amines, as well 
as a three-step synthesis of imatinib, the active pharmaceutical 
ingredient of the anti-cancer agent Gleevec® under continuous 
flow conditions. Notably, these multistep reaction syntheses 
were performed without in-line purification of any intermediates 
or solvent exchanges between steps. 
We have previously reported a system where biphasic 
conditions were utilized for C–N cross-coupling. However, even 
though phase-transfer catalyst additives were able to greatly 
increase the efficiency of the reaction, the generality of such a 
system was still severely impaired by the solubility of reagents 
and products in toluene, particularly heteroaromatic compounds. 
We envisioned that DMO would be a practical solution for 
continuous flow chemistry due to its similar Hansen solubility 
parameters to dichloromethane6b, low solubility in water (4.3 
g/L)6c, reported toxicological profile comparable to common 
laboratory solvents6c,d, ready availability as a high production 
volume chemical,6c and previous use as a crystallization inhibitor 
and for crop protection formulations.6,7 We therefore evaluated 
its use in the cross-coupling of aniline (2) and 4-chloroanisole (3) 
in the presence of XPhos-based8 precatalyst 7 under biphasic 
conditions with aqueous KOH as the base. When the reaction 
was performed in a perfluoroalkoxyalkane (PFA) tube reactor 
with neat DMO as the solvent, low conversion was observed, 
presumably due to inefficient mixing of the two phases (Table 1, 
entry 1). The use of a stainless steel packed-bed reactor 
apparatus,4a a device previously described for achieving efficient 
mixing in a biphasic flow system, improved the yield significantly 
(Table 1, entry 2). Full conversion and excellent yield were 
obtained when the BrettPhos-based9 precatalyst 8 was used 
instead of 7 (entry 3). Further optimization revealed that 
toluene/DMO mixtures containing as little as 10% DMO gave 
similar results to DMO as a neat solvent (entry 4 and 5). In 
addition, we found that 2-methyltetrahydrofuran (2-MeTHF), a 
solvent derived from renewable sources and suitable for large-
scale production,10 also gave comparable results when 10% 
DMO was utilized as an additive (entry 6). Control experiments 
showed that the use of toluene or 2-MeTHF in the absence of 
DMO resulted in incomplete conversion of starting material 
within the designated reaction times. Upon extended reaction 
[a] J. Yang, D. Niu, B. Karsten, F. Lima and Prof. Dr. S. L. Buchwald 
Department of Chemistry, Room 18-490 
Massachusetts Institute of Technology 
Cambridge, MA 02139 (USA) 
E-mail: sbuchwal@mit.edu 
 Supporting information for this article is given via a link at the end of 
the document.((Please delete this text if not appropriate)) 
COMMUNICATION          
 
 
 
 
times to achieve full conversion in toluene (entry 7), the reaction 
vessel clogged due to the poor solubility of the product. Although 
the use of amphiphilic solvent 9 also gave high conversion of 
starting material and yield of product 4, clogging of the reactor 
occurred after prolonged reaction times. Therefore, the 
conditions in entry 5 or 6 of this table were selected for most of 
the following studies. 
 
Table 1. Optimization of the palladium-catalyzed C–N cross-coupling reaction 
under continuous flow conditions.[a] 
[a] Conversions and yields were determined by GC analysis of the crude 
reaction mixture. See supporting information for details. [b] 0.04” PTF tubing 
was used as the reaction vessel. [c] Prolonged reaction times resulted in full 
conversion along with clogging of the reaction vessel due to the low solubility 
of the product. 
 
Using the above-described conditions, we explored the 
generality applicability (Table 2). A wide variety of aryl bromides 
and chlorides, bearing electron-donating or -withdrawing 
substituents, were efficiently coupled with aniline partners (10a-
b, and g-h). Ortho-substitution in either aryl halide or arylamine 
reaction partner was accommodated (10c-e). In addition, aryl 
triflates (10f) were also excellent substrates under these 
conditions, with minimal hydrolysis observed. Besides aryl 
amines, primary alkyl amines could also successfully converted 
to product (10g). As a consequence of the precise control of 
reaction times under continuous flow conditions, even readily 
hydrolyzed methyl esters provided high yield of desired product 
(10b-e, and 10h). To demonstrate the potential applicability of 
this method, fenofibrate, a medicine used to reduce cholesterol 
levels, was subjected to the reaction conditions and coupled with 
3-trifluoromethylaniline to give 10h in excellent yield. 
 
 
 
 
 
 
 
 
Table 2. Substrate scope of C–N cross-coupling reaction between arylamines 
and aryl (pseudo)halides.[a] 
[a] Isolated yields are reported (average of 2 runs, approximately 1 - 4 mmol 
collected). See supporting information for details. 
 
Next, we turned our attention to expanding the scope of this 
method to include heteroaromatic compounds. The results are 
summarized in Table 3.  
 
Table 3. Substrate scope of C–N cross-coupling reaction between 
heteroarylamines and heteroaryl (pseudo)halides[a] 
[a] Isolated yields are reported (average of 2 runs, approximately 1 - 4 mmol 
collected). See supporting information for details. 
 
A variety of heterocycles, including pyridines (11a-c), thiophene 
(11d), benzothiazole (11e), quinoline (11f), piperazine (11g), 
and phenothiazine (11h), were efficiently coupled with aromatic, 
heteroaromatic, or aliphatic amine partners. Notably, 
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chlorpromazine, an anti-psychotic drug, could be coupled with 2-
aminopyridine under these conditions to give 11h in excellent 
yield. Substrates containing base-sensitive functional groups like 
ketones (11d) and esters (11g) were again well tolerated under 
these continuous flow conditions.  
In light of the broad scope demonstrated by our reaction 
conditions, we next explored the potential of integrating this C–N 
cross-coupling reaction into multistep sequences in flow. In this 
context, we were interested in converting phenols to 
biarylamines via aryl triflate intermediates (Scheme 1). Aryl 
triflates are recognized as highly reactive coupling partners in 
C–N cross-coupling reactions. However, the lack of 
commercially available triflates and their instability necessitate 
their preparation prior to their use in later reactions, which 
significantly hampers their application. We reasoned that the 
two-step conversion of phenols to arylamines without isolating 
the triflate intermediate would be of considerable interest. We 
have previously reported a similar sequence in flow, the 
complete removal of methylene chloride from the first step via 
microfluidic distillation and solvent exchange to 
dimethylformamide was required for a subsequent Heck 
coupling.2f After experimentation, we found that this could be 
accomplished in a flow system as shown in Scheme 1. While the 
triflation of a phenol often is carried out at low temperature and 
with the slow addition of triflic anhydride in a batch reactor,11 this 
transformation could be performed at room temperature in 
minutes using aqueous K3PO4 as the base in a continuous flow 
reactor. The reaction mixture from the first step was directly 
introduced into another packed-bed reactor with an aryl amine 
substrate, Pd precatalyst 8, and additional K3PO4 to give the 
desired biarylamine product in excellent yields over two steps 
(12a-b). In contrast to previous reports of the use of in situ 
generated aryl triflates in continuous flow, no in line purification 
or solvent switch were required in this process. In addition, we 
found that a phenol tosylation/C–N cross-coupling sequence 
could also be similarly accomplished (12c).12 
 
Scheme 1. Two step flow conversion of phenols to biarylamines via aryl 
triflates or tosylates.[a]  
a] Isolated yields are reported (average of 2 runs, approximately 1 - 4 mmol 
collected). See supporting information for details. 
 
To further demonstrate the utility of this C–N cross-coupling 
technology, we applied it in a flow-based synthesis of imatinib 
(19, Scheme 3), a tyrosine kinase inhibitor widely used in the 
treatment of chronic myeloid leukemia.13 In an elegant 
demonstration of the power of flow methodology in the 
preparation of important pharmaceutical substances, Ley2g,h 
described the flow synthesis of imatinib, as depicted in Scheme 
2. Based on this synthetic sequence, Ley reported a flow 
synthesis of imatinib featuring the sophisticated use of an in-line 
solvent switching apparatus, solid supported reagents, and 
purification cartridges to provide imatinib with minimal manual 
handling of intermediates. The final product was purified by 
chromatography to provide pure imatinib in 32% overall yield. 
 
Scheme 2. Three step flow synthesis of imatinib. 
Scheme 3. Flow synthesis for imatinib. 
 
We have also reported on the synthesis of imatinib using 
batch protocols.15 Using our new C–N cross-coupling technology, 
a more streamlined continuous flow process for the synthesis of 
imatinib is depicted in Scheme 3. The first step, coupling of 3-
bromo-4-methylaniline (13) with 4-chloromethyl-benzoyl chloride 
(14) to form amide (15), was performed in a 2-MeTHF/H2O 
biphasic system with KOH as the base (Schotten-Baumann 
conditions14). Complete conversion was achieved within three 
minutes at room temperature and the product 15 could be 
isolated in 87% yield. The next reaction step, the nucleophilic 
substitution of the benzylic chloride 15 with 1-methylpiperazine 
(16), was implemented by directly using the output of the first 
reactor. An aqueous solution of 16 was injected into the system 
and the mixture was pumped through a packed-bed reactor at 
120 °C. The residence time in the second reactor was 15 
minutes and the reaction yield over the first two steps was 84% 
as determined by 1H-NMR of the crude reaction mixture. The 
last step in the synthesis of imatinib is the C–N cross-coupling of 
15 with 2-aminopyrimidine 18 using precatalyst 8 (5 mol %). The 
outlet of the previous reactor was again used directly. Due to the 
high selectivity of BrettPhos for the coupling of primary amines,9 
it was not necessary to remove the excess 1-methylpiperazine 
(16) from the reaction mixture. To address the low solubility of 
18 in organic solvents, it was converted to its conjugate acid, 
and injected into the system as an aqueous solution. As was 
done for C–N couplings described earlier, the reaction was 
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performed in a packed-bed reactor in order to maximize mixing 
of the two phases. The residence time in the last reactor was 15 
minutes. Imatinib was isolated in 56% overall yield from the 
crude reaction mixture via acid/base extraction followed by 
trituration in acetonitrile.16 No solvent exchange or purification of 
intermediates was necessary throughout the whole synthesis. 
In conclusion, we have demonstrated the generality of a 
flow-based C–N cross-coupling reaction featuring the use of 
DMO as an organic co-solvent in a biphasic system. The use of 
the biphasic system serves as a convenient solution to address 
the precipitation of inorganic byproduct generated during C–N 
cross-coupling reactions. A wide range of biarylamines, 
including those derived from commercial drugs, have been 
made in short reaction times. This C–N cross-coupling 
methodology employed KOH as the inorganic base and yet was 
compatible with sensitive functional groups. To further illustrate 
the utility of this method, we have integrated this method into a 
two-step flow sequence that converts phenols into biarylamines, 
via the intermediacy of triflates or tosylates. We have also 
showcased this technology in the three-step synthesis of the 
anti-cancer agent imatinib. Compared with previous synthetic 
routes, our synthesis does not require in-line manipulation of 
reaction intermediates or solvent exchange between steps, uses 
lower catalyst loading, and produces the target product in higher 
overall yield. We expect this strategy of using DMO as a co-
solvent in biphasic system to be applicable to other multistep 
flow sequences, especially those involving cross-coupling 
reactions. 
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